Skip to main content

Table 4 Relative efficacy versus abatacept + MTX at 24/26 and 48/54 weeks

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Treatment effect relative to Abatacept + MTX Difference in mean HAQ CFB
at 24/26 weeks
(95% CrL)*
Difference in mean HAQ CFB
at 48/54 weeks
(95% CrL)**
OR for ACR-50
at 24/26 weeks
(95% CrL)*
OR for ACR-50
at 48/54 weeks
(95% CrL)**
OR for DAS28 < 2.6
at 24/26 weeks
(95% CrL)*
OR for DAS28 < 2.6
at 48/54 weeks
(95% CrL)*
Placebo + MTX -0.30
(-0.41; -0.18)
-0.29
(-0.38; -0.21)
3.37
(1.49; 8.06)
3.84
(2.84; 5.26)
4.77
(1.60; 15.78)
8.82
(1.50; 57.83)
Adalimumab + MTX 0.03
(-0.16; 0.24)
0.05
(-0.09; 0.18)
0.40
(0.09; 1.50)
0.56
(0.29; 1.03)
  
Certolizumab Pegol + MTX 0.08
(-0.09; 0.28)
0.13
(-0.00; 0.26)
0.35
(0.08; 1.33)
0.51
(0.26; 0.96)
0.26
(0.01; 3.90)
 
Etanercept + MTX -0.02
(-0.24; 0.21)
0.05
(-0.22; 0.32)
1.05
(0.17; 3.24)
0.72
(0.43; 1.19)
1.69
(0.21; 15.80)
2.94
(0.14; 67.12)
Golimumab + MTX 0.04
(-0.21; 0.30)
  0.87
(0.16; 5.15)
  1.18
(0.13; 11.66)
 
Infliximab + MTX -0.11
(-0.29; 0.08)
-0.11
(-0.22; 0.01)
1.31
(0.27; 7.61)
1.40
(0.93; 2.10)
0.88
(0.09; 7.76)
1.68
(0.14; 21.23)
Rituximab + MTX -0.09
(-0.31; 0.14)
0.01
(-0.34; 0.35)
0.85
(0.20; 3.47)
0.31
(0.04; 1.37)
  
Tocilizumab + MTX -0.09
(-0.35; 0.18)
  0.51
(0.10; 2.88)
  0.05
(0.00; 0.79)
 
  1. Note: for HAQ CFB, negative values indicate a trend towards a clinical benefit for abatacept. For ACR-50 and DAS28 < 2.6, an OR > 1 indicates a trend towards a clinical benefit for abatacept.
  2. * Results based on a random effects model. ** Results based on a fixed effects model.
  3. OR, odds ratio; 95% CrL, 95% credible limits